

Nutraceuticals in Viral Infection

Subjects: **Nutrition & Dietetics**

Contributor: Giorgio Costagliola

Nutraceuticals, including vitamin D, vitamin A, zinc, lactoferrin, polyphenols coenzyme Q, magnesium, and selenium, are implicated in the modulation of the complex molecular pathways involved in the immune response against viral pathogens. A common element of the activity of nutraceuticals is their ability to enhance the innate immune response against pathogens by acting on the major cellular subsets and inducing the release of pro-inflammatory cytokines and antimicrobial peptides. In some cases, this action is accompanied by a direct antimicrobial effect, as evidenced in the specific case of lactoferrin. Furthermore, nutraceuticals act through complex molecular mechanisms to minimize the damage caused by the activation of the immune system against pathogens, reducing the oxidative damage, influencing the antigen presentation, enhancing the differentiation and proliferation of regulatory T cells, driving the differentiation of lymphocyte subsets, and modulating the production of pro-inflammatory cytokines.

polyphenols

resveratrol

vitamin A

vitamin D

zinc

lactoferrin

magnesium

selenium

coenzyme Q

1. Introduction

Nutraceuticals are products derived from food that play a role in maintaining well-being, enhancing health, modulating immunity, and thereby preventing as well as treating specific diseases (**Figure 1**) ^[1]. Nutraceuticals have complex interactions with the immune system, with the potentiality to improve the response against pathogens but also to modulate the activation of immunity itself ^[2]. Given their immunomodulatory activities, for years they have been the subject of studies not only to clarify their complex biological mechanisms, but also to assess their possible applications in clinical practice, for the maintenance of good general health and the prevention of pathological conditions including infections, chronic inflammatory or autoimmune diseases, and allergic diseases ^[3]. Concerning viral infections, the optimal functioning of the innate and adaptive immune response is essential in the defense against pathogens and allows the clearance of the infectious agent and the generation of an immunological memory, which prevents reinfection by the same pathogen. However, when the innate or adaptive immune response is activated in an uncontrolled way, the immune system itself could be responsible for the development of tissue damage, thus representing a “double-faced weapon”. Therefore, there is increasing interest in strategies to potentially modulate the activation of the immune response against viral infections, to reduce immune- and inflammatory-induced organ damage while maintaining (and potentially enhancing) the capability to prevent infection or adequately eliminate the infectious agent. In this paper, we review the main molecular mechanisms responsible for the immunomodulatory function of nutraceuticals, with a particular

focus on vitamin D, vitamin A, lactoferrin, zinc, polyphenols, coenzyme Q, magnesium, and selenium, in order to update clinicians on the benefit of using nutraceuticals for the management and the prevention of allergic diseases and viral infections.




Figure 1. Role of nutraceuticals in health and disease.

2. Vitamin D

Vitamin D (VD) is a fat-soluble hormone mainly synthesized in the skin during exposure to sunlight (UVB radiation) through the conversion of 7-dehydrocholesterol to biologically inactive vitamin D3. This undergoes hydroxylation in the liver by 25-hydroxylase to become 25(OH)D, the major circulating form of VD in humans. In the kidney, 25(OH)D is further converted to the active metabolite 1,25(OH)D by the 1- α -hydroxylase [4]. Vitamin D 1,25-OH acts on target cells via the VD receptor (VDR), which binds specific sequences, called "VD responsive elements", through which it acts as an activator or repressor of transcription of several genes. Although VD plays a fundamental role in phospho-calcium homeostasis, recent studies have shown that it has numerous extra-skeletal actions, including important immunostimulant and immunomodulatory properties. These observations suggest a key role for VD in the modulation of immune function, above all during pediatric age, as high levels of VD are important to prevent viral respiratory infections. A relationship between VD status and the incidence or the severity of respiratory infections in children has been found in many observational studies, and a recent review seems to support the protective role of VD against tuberculosis, otitis media, pharyngotonsillitis, bronchiolitis, and viral wheezing [5][6][7]. Even during the recent COVID-19 pandemic, VD and its metabolites were found to be useful both in inducing the antiviral response and in negatively regulating the renin-angiotensin-aldosterone system, including the expression of ACE2, the receptor for SARS-CoV2 [8][9]. The influence of VD status on the clinical outcome of patients with COVID-19 is still undefined, as studies have shown conflicting results [10][11][12]. However, there is increasing interest in the potential influence of several age-related factors (function and maturation of innate and adaptive immunity, ACE2 expression, comorbidities) and the nutritional status on the clinical course of SARS-CoV-2 infection [13][14]. Although systemic levels of VD are regulated on phospho-calcium metabolism, tissue production

of VD by cells expressing 1 α -hydroxylase is regulated by calcium-independent mechanisms and can significantly influence the immune response through autocrine and paracrine mechanisms [4][15].

2.1. Antimicrobial Activity

The action of VD on the immune system is extremely complex, as VDR is expressed by many cells involved in the inflammatory response and the innate and adaptive immune response. Indeed, VD modulates cytokine secretion, through its action on the VDR receptor, and controls the function of lymphocyte subpopulations, both directly and by influencing the function of antigen-presenting cells (APCs), which are responsible for the expression of co-stimulatory molecules that are essential for the activation of the immune response [16]. Cells of innate immunity and epithelial cells, particularly in the airways, can synthesize vitamin D 1,25-OH locally through the expression of 1 α -hydroxylase. The expression of this enzyme is stimulated by various mechanisms, including the action of interferon (IFN- γ), the activation of toll-like receptors (TLRs) involved in the innate immune response, and the cellular pathways they control (JAK/STAT pathway, NF- κ B pathway), and is, therefore, a phenomenon that amplifies the immune response itself [16][17]. In addition, VD increases the chemotaxis of cells of innate immunity, their microbicidal activity, autophagy, and the production of defensins and cathelicidins, soluble mediators with an antimicrobial function [18]. VD also contributes to the immune response by causing an enhancement of epithelial barrier function in both the skin and the lung, stimulating the maturation of type II pneumocytes, promoting surfactant production, and increasing the innate immune response in airways. In the gut, VD induces the expression of occludins and claudins, thereby increasing the integrity of the mucosal barrier. In addition, intestinal mucosal homeostasis is also influenced by modulation of the local microbiome, which in turn is essential in the development of immunological tolerance and is linked to the systemic immune system via a complex system of interactions known as the “gut-immune system axis”. This action ultimately results in a protective effect against gastrointestinal infections and modulation of the secretion of pro-inflammatory cytokines [19].

2.2. Immunomodulation

VD prevents excessive activation of the inflammatory and immune response by reducing the excessive release of interleukin-1 β (IL-1 β) and IL-6, as demonstrated in patients with sepsis. VD contributes to maintaining adequate plasmatic levels of dendritic cells (DCs) and promotes a “tolerogenic” phenotype of dendritic cells (DCs), which is featured by reduced production of IL-12 and increased synthesis of IL-10 [17][19]. Additionally, VD reduces the activation of T-helper-1 (Th1) and Th17 cells, resulting in reduced production of pro-inflammatory cytokines (IFN- γ , IL-12, and IL-17) and the consequent tissue damage [18][20]. Finally, VD promotes the differentiation and proliferation of regulatory T cells (Tregs) and Th2 cells in both healthy individuals and patients affected by inflammatory disorders [21][22], influences lymphocyte homing (and, therefore, the activation of adaptive immunity), and causes a reduction of memory B cell differentiation and immunoglobulin production [14][23][24]. The molecular mechanisms responsible for these effects are not completely elucidated. The influence of VD on T CD4+ cells is extremely complex and involves the stimulation of the FOXP3 and GATA3 transcription factors (which drive Treg and Th2 proliferation, respectively) and the inhibition of IL17A gene expression [18]. On the other hand, the effects

on B cells and immunoglobulins are mostly mediated by the negative regulation of Nf-KB and the reduction of costimulatory signals [25], while the basis of the action on DCs is far from being fully understood.

Concerning the threshold for VD supplementation, several scientific societies have established that 25(OH)D levels higher than 20 ng/mL are sufficient to ensure optimal bone health, while 25(OH)D levels higher than 30 ng/mL are needed to favor VD extra-skeletal actions [26][27]. Notably, the use of VD supplementation in the prevention and treatment of several immune-mediated disorders (systemic lupus erythematosus (SLE), multiple sclerosis, inflammatory bowel diseases) has shown promising results [18]. Moreover, the influence on the immune response (particularly on thymic output and DCs) has been demonstrated also in patients with immunodeficiency affecting T-cell function, which represents a population carrying a higher risk of severe viral infections [28]. Therefore, the identification of high-risk patients could lead to an optimization of VD supplementation strategies.

3. Vitamin A

The term vitamin A (VA) refers to a large group of fat-soluble elements, including retinol, retinoids, and carotenoids. The active metabolite retinoic acid is of particular clinical interest, as it is involved in numerous functions, such as regulation of cell differentiation, control of oxidative stress, and modulation of the immune response. Retinoic acid is synthesized through a series of enzymatic reactions and binds to its nuclear receptor (retinoic acid receptor: RAR), which interacts with specific sequences, termed “retinol-responsive elements” at the promoter level of target genes, influencing their transcription [29]. The suggested daily requirement of VA, expressed in micrograms of retinol (1 mcg retinol = 6 mcg beta-carotene = 12 mcg other provitamin carotenoids), is 450 mcg in infants, 300–500 mcg in school-age children, and 600–700 mcg in adolescence. VA deficiency is defined by plasma concentrations of less than 20 mcg/dL. Currently, the World Health Organization (WHO) recommends supplementation with 100,000 IU of vitamin A between 6 and 12 months of age and 200,000 IU from 12 months to 5 years of age, taken every six months orally [30]. VA supplementation has also been shown to be effective in the prevention and treatment of viral gastrointestinal infections in terms of reduced severity and days of illness; zinc and VA supplementation has been associated with faster resolution of diarrheal symptoms in developing countries [31][32].

3.1. Antimicrobial Activity

The action of retinoic acid on the immune system is of particular importance with regard to gastro-intestinal mucosal immunity, where it can influence the proliferation, activity, and migration of APCs and cells of adaptive immunity [33]. Similar to VD, VA can modulate the composition of the gut microbiome and directly stimulate the synthesis of proteins involved in maintaining the integrity of the gastrointestinal barrier [34]. Indeed, VA deficiency is associated with an increased burden of infectious disease [35]. The anti-infective and immunomodulatory actions of retinoic acid partly depend on its synthesis by DCs. In particular, DCs located in the mesenteric lymph nodes and Peyer's patches, and those located in the skin and lungs, express the enzyme retinal dehydrogenase (RALDH) and can synthesize retinoic acid both constitutively and in response to infectious stimuli (bacteria, viruses, parasites) [29][34]. Through the interaction with retinoid X receptors (RXRs), retinoic acid is involved in modulating

the function of DCs themselves and their ability to present antigens as well as stimulating the differentiation of specific dendritic cells with a tropism for the intestinal mucosa. Indeed, it promotes their maturation, activation, antigen-processing, and antigen-presenting capacity and may also influence the maturation and tissue tropism of T and B lymphocytes, also enhancing the proliferation of T lymphocytes and increasing their cytotoxic activity [34][36]. The action on T cells partly depends on the enhancement of IL-2 secretion and signaling, IL-22 production, and the expression of gut-homing receptors [24]. Finally, it stimulates isotypic switch and IgA production, thus significantly improving mucosal immunity [37]. This latter effect, which requires adequate mucosal concentrations of IL-5 and IL-6, is mediated by the stimulation of the inducible nitric oxide synthase (iNOS) enzyme and by the modulation of the gut-associated lymphoid tissue (GALT) DCs activity [24][38]. Accordingly, in experimental models of VD deficiency, a reduced mucosal IgA concentration was observed [24][39].

3.2. Immunomodulation

VA is not only involved in immunomodulation during the infectious response but also seems to play an important role in modulating the inflammatory and immune response (Figure 2). Indeed, it could influence the Th1-Th2 balance, favoring the Th2 response [40]. This effect mostly depends on the influence on transcription factors, including the stimulation of GATA3, STAT6, and IL4 genes (implicated in Th2 differentiation) and the inhibition of Tbet, which is involved in Th1 differentiation [41]. Additionally, VA induces Treg differentiation, both directly (activating FOXP3) and through its action on DCs, and promotes Treg tropism for the intestinal mucosa by stimulating the expression of gut-specific receptors (i.e., CCR9 and α 4 β 7 integrin) [42]. Interestingly, the modulation of different transcription factors by retinoic acid participates in the regulation of the Treg-Th17 balance, as the differentiation of these subpopulations is mutually regulated. Experimental studies demonstrated that low concentrations of retinoic acid could promote Th17 differentiation and inhibit Tregs, while higher concentrations mediate the opposite effects, finally contributing to mucosal immune tolerance [39]. Interestingly, it has recently been shown that retinol deficiency in transplant patients is associated with a higher incidence of Graft Versus Host Disease (GVDH), especially intestinal, through reduced gastrointestinal permeability, higher rate of mucosal injury, and reduced lymphocyte homing to the gut [43].




Figure 2. Action of nutraceuticals on the immune balance.

4. Zinc

Zinc has a key role in numerous signaling pathways and cellular processes involved in the activation and modulation of the immune response to viral infections [44]. Studies on the use of zinc in the prevention and treatment of respiratory and gastrointestinal viral infections have shown conflicting results. Indeed, while many studies demonstrated that zinc could reduce the incidence and severity of upper respiratory infections, other authors found no effect, and zinc seems not to influence the prevention and clinical course of lower respiratory infection [3][9].

4.1. Antimicrobial Activity

At a molecular level, zinc can act as a signaling molecule, to reversibly bind the regulatory subunits of proteins implicated in immune pathways and to regulate the composition and permeability of the cell membrane [45][46]. Moreover, it is essential in maintaining the structural and functional integrity of different enzymes (kinases, phosphatases, caspases, and others) involved in the immune response [45]. Interestingly, the acute (zinc flux, zinc waves) and chronic (homeostatic zinc signals) variations in cellular zinc concentration can activate different molecular pathways, and this could partly explain the promoting effect on immune activation during acute antigenic stimulation (viral infection) and the inhibition of the immune response following the chronic stimulation of the immune system. The anti-infectious properties of zinc depend on the direct interaction with viral replication and on the stimulation of antiviral immunity. In vitro studies have demonstrated that zinc can inhibit viral replication of different pathogens of the upper and lower airways, including influenza A virus and respiratory syncytial virus (RSV), with a mechanism that involves the interference with DNA and RNA polymerase activity [9][47]. The enhancement of the innate immune response against pathogens strongly contributes to zinc's antiviral properties.

In vitro, the binding of TLR4 with the lipopolysaccharide (LPS) is followed by an acute intracellular zinc flux, which promotes the activation of NF- κ B, central in the production of acute-phase proteins and pro-inflammatory cytokines [48]. Moreover, zinc stimulates the production of IFN and other antiviral proteins as well as the proliferation of cells involved in the innate (macrophages, neutrophils, natural killer (NK) cells) and adaptive immune response and enhances NK cell lytic activity and function [49]. Concerning adaptive immunity, zinc has a key role in the differentiation and proliferation of T cells, being a cofactor for the thymocyte-derived hormone thymuline [44][50]. Although the proliferation of B cells seems not to be influenced by zinc [51], it promotes antibody production and influences isotypic switch through the influence on specific transcription factors and cytokine signaling (i.e., IL-4-mediated phosphorylation of STAT6 in the class switch favoring IgE production) [45][52]. Accordingly, patients with zinc deficiency show reduced adaptive immune response and higher susceptibility to the development of severe infections compared to the general population [49]. However, recent studies suggest that zinc deficiency is also more common in patients with autoimmune diseases, thus underlying its role in modulating the immune response [53].

4.2. Immunomodulation

Persistent antigenic stimulation (i.e., in patients with chronic viral infections or autoimmune diseases) produces chronically elevated cellular levels of zinc. This long-term elevation of zinc levels causes NF- κ B inhibition, with consequently reduced release of pro-inflammatory cytokines (IL-1 β , tumor necrosis factor- α (TNF- α)), lipid peroxidation, and release of reactive oxygen species (ROS) [46][49][50][54]. The mechanism underlying the inhibition of Nf-KB seems to be mostly dependent on the effect of zinc on the anti-inflammatory zinc-finger protein A20 and the peroxisome proliferator-activated receptor- α (PPAR- α) [46]. The immunomodulatory role of zinc depends also on its effect on adaptive immunity. Indeed, zinc is implicated in the enhancement of TGF- β -induced signaling and in the activation and stabilization of FOXP3, thus finally driving the differentiation of CD4+ lymphocytes into Tregs. The influence of zinc on lymphocyte subpopulation is also confirmed by the reduced Th1 response, with a Th1-Th2 imbalance observed in patients with zinc deficiency, although the molecular mechanism is not well defined [51]. Finally, zinc influences the intracellular cascades that follow the activation of the T-cell receptor (TCR), B-cell receptor (BCR), and cytokine receptors. It regulates the expression of NFAT transcription factor, which promotes IL-2 production in activated lymphocytes and inhibits calcineurin (implicated in NFAT activation) [45][55], but also enhances the phosphoinositide 3-kinase (PI3K)-induced signaling, activated after the binding of TCR and BCR with their ligands. Therefore, zinc interferes with a wide range of activating and inhibitory molecular pathways in the complex network that follows lymphocyte activation [45][56]. Concerning cytokines, in vitro and experimental studies have evidenced that zinc deficiency causes an enhanced biological effect of IL-6 and IL-2 [54], which are implicated in the maintenance of the inflammatory response and lymphocyte proliferative response. On the other hand, zinc deficiency has the opposite effect on IL-4 signaling, thus resulting in an imbalanced immune function [52].

5. Lactoferrin

Lactoferrin is a glycoprotein physiologically present in breast milk, with higher concentrations in colostrum, and represents a key factor in the newborn innate immune system [57][58], with its supplementation in pre-terms being

associated with a reduced incidence of late-onset sepsis [59]. The antibacterial properties of lactoferrin are well known and derive from its capability to bind and sequestrate iron (bacteriostatic effect), from the direct bactericidal effect (particularly in Gram-negative LPS-producer bacteria), and from the capability to activate the complement cascade [60][61][62]. In addition, the antiviral and immunomodulatory properties of lactoferrin are of great interest and have been the subject of a wide number of clinical and preclinical studies. Although preclinical studies have helped in clarifying the main molecular mechanisms, the clinical applications in the field of viral infections are still to be completely defined. However, the most recent clinical studies investigating the effect of lactoferrin supplementation on the prevention and treatment of viral infections showed promising results, as different authors evidenced a reduction of the frequency and severity of viral gastroenteritis in infants and a reduced incidence of cold in adults [57][63][64].

5.1. Antimicrobial Activity

The antiviral effects of lactoferrin depend on the inhibition of different phases of the infectious cycle. Indeed, it can interfere with the binding of viral pathogens with heparin sulfate glycosaminoglycan molecules on the cellular surface, thus blocking the interaction between the virus and its receptor and its entry into the host cell [57][60]. In vitro studies performed on different pathogens (influenza A virus, parainfluenza virus, RSV, and others) evidenced that lactoferrin inhibits viral replication, with an effect that is more pronounced when adequate cellular zinc levels are present [9][57]. Additionally, lactoferrin has complex immunostimulating properties that promote viral clearance, enhancing both innate and adaptive responses [65]. The effect of lactoferrin on the different cellular targets is mediated by its interaction with cellular receptors (surface peptidoglycans and glycosaminoglycans, TLRs, and others), which promote its internalization. Following this, lactoferrin can act through the modulation of signaling pathways (interacting with kinases and phosphatases) and transcription factors [62]. Concerning the innate response, lactoferrin acts as a chemotactic factor for leukocytes, enhancing cellular activity, cytokine release (particularly IFN), and function of NK cells (thus promoting phagocytosis), neutrophils, and macrophages, and participates in reinforcing and maintaining the integrity of the gut mucosal barrier [61][66]. Different studies have shown that lactoferrin accelerates the maturation of enterocytes (mainly through the activation of MAP kinase (MAPK)-dependent molecular pathways), thus reducing the permeability of the mucosal barrier and the systemic spreading of infectious agents, and promotes the development of the gut microbiome [65][67]. This latter effect is of particular relevance in newborns, since the microbiome prevents gut colonization by pathogens [66] and has a direct local and systemic immunomodulatory role through the stimulation of the release of IL-10 [68] and the downregulation of Th1- and Th17-dependent cytokines [69]. The action on innate immunity is also partly responsible for the effects of lactoferrin on the adaptive immune response. Indeed, lactoferrin stimulates the maturation and activation of DCs and macrophages and enhances their antigen-presenting function and secretion of cytokines (such as TNF- α , IL-8, and IL-12), finally promoting a Th1-mediated immune response [70]. Additionally, lactoferrin directly influences lymphocyte maturation and proliferation, as different experimental studies showed that lactoferrin enhances the maturation of T helper lymphocytes and B lymphocytes and their antigen-presentation function as well as the production of immunoglobulin, both at the mucosal level and systemically [65][71][72]. Activation of MAPK pathways contributes to the promoting effect of lactoferrin on T cell maturation, while the enhanced release of IL-12 is important in driving Th1 differentiation [65][73].

5.2. Immunomodulation

The recently described immunomodulatory activity of lactoferrin mostly depends on its influence on the function of innate immune cells and mediators. Lactoferrin can cause a reduced inflammatory response by pathogen-infected cells and reduced activation of antigen-presenting cells (particularly DCs) [74] in case of exuberant inflammation. Additionally, it can reduce the release of a wide range of pro-inflammatory cytokines, including TNF- α and IL-6 [61] [75], the production of chemotactic factors, and the expression of adhesion molecules, such as ICAM-1 and E-selectin [65] [76]. At the molecular level, these effects partially depend on a direct interference with the TLR4-LPS interaction, through the binding of circulating LPS and the interaction with TLR4 [70] [77]. Moreover, lactoferrin can bind to TLR2, TLR9, and other danger signal receptors, thus influencing the intracellular pathways of the inflammatory response [78]. The inhibition of lipid peroxidation and the induction of enzymes with antioxidant properties (i.e., superoxide dismutase) contribute to the reduction of the ROS-induced damage [79] [80], which has a relevant role in viral infections. The effects of lactoferrin on the adaptive immune system are multiple, as the molecule can promote both the stimulation and the inhibition of lymphocyte proliferation and differentiation, with mechanisms that are not completely defined [76]. Concerning this, in contrast with the previously described effects on the promotion of adaptive response, both *in vitro* and experimental studies have evidenced that lactoferrin can reduce the activity of the TLR-NF- κ B axis [77] [79]. This mechanism partially contributes to the effect of lactoferrin in reducing T cell activation (particularly the Th1 response) and secretion of pro-inflammatory cytokines [70], thus minimizing the tissue damage that follows the activation of the immune and inflammatory response against pathogens.

6. Polyphenols

The polyphenol family includes a wide number of molecules, classified into flavonoids and non-flavonoids, of which resveratrol is the most studied for its clinical applications. Single molecules of the polyphenol family can show different interactions with the cells and mediators of the immune system, and both immunostimulating and immunomodulating effects are observed [81] [82]. Clinical studies on viral infections are still limited, but evidence suggests a promising role for resveratrol in the prevention and mitigation of respiratory infections [83].

6.1. Antiviral and Immunomodulating Properties of Resveratrol

The molecular actions of resveratrol contribute to favoring the clearance of viral pathogens and the reduction of immune- and inflammation-mediated damage. Concerning the antiviral properties, *in vitro* studies have demonstrated that resveratrol can inhibit the replication of RSV, SARS-CoV2, and other viral pathogens, and interferes with different phases of the viral replication cycle [84] [85].

The immunomodulating properties of resveratrol are mostly mediated by its interaction with SIRT1, a protein implicated in numerous signaling and transcription pathways, modulation of immune cell proliferation and activation, inhibition of cyclo-oxygenase 2 (COX-2) enzyme, and regulation of oxidative damage [86]. The antioxidant role of resveratrol has been extensively studied and depends on its ability to influence mitochondrial

functioning [87]. Indeed, resveratrol causes transcriptional modifications that carry an enhanced expression of superoxide dismutase, catalase, and glutathione peroxidase, thus reducing cellular oxidative stress [87][88][89]. The stimulation of SIRT1 is also involved in the downstream of NF- κ B-dependent molecular pathways in cells of the innate and adaptive immune system [86]. This effect, which partly depends on the interaction with the Nf-KB subunit p65 and on the degradation of the inhibitor protein- κ B α (IkB α), is responsible for a reduced secretion of TNF- α , IL-1 β , IL-6, and other inflammatory mediators by innate immune cells [86]. Experimental studies have shown that resveratrol can reduce the surface expression of TLRs (particularly TLR4) by cells of the innate immune system and lead to a downregulation of TLR-mediated response (i.e., MAPK activity) [86][90]. This effect is particularly relevant for patients with chronic viral infections and immune-mediated diseases, such as SLE, in which TLR activation plays an important pathogenic role [91]. However, the effects of resveratrol on the release of cytokines are not of unequivocal interpretation, as in vivo studies have evidenced that supplementation with resveratrol reduces the serum levels of macrophage-derived cytokines, while those produced by lymphocytes were found to be augmented [92]. Concerning this, it is reasonable to hypothesize that resveratrol could reduce the chronic inflammatory burden evidenced in several immune-mediated diseases and chronic infections while enhancing the systemic adaptive response to viral pathogens. The immunomodulatory effects on adaptive immunity include the reduced proliferation and differentiation of B cells and Th17 cells, reduced antibody production, enhanced production of IL-10, and interference with the activation of self-reactive T cells, while the influence on the absolute number of T-reg is controversial [86][93][94]. The effects on T cells are mediated by Sirt1, which blocks the translocation of c-Jun (central in the progression of cell cycle and inhibition of apoptosis) to the nucleus [95]. On the other hand, the modulation of humoral immunity involves the upregulation of the inhibitory molecule Fc γ RIIB on B cells, which results in decreased antibody production [86].

6.2. Antiviral and Immunomodulating Properties of Other Polyphenols

Quercetin is a flavonoid with marked anti-inflammatory properties. In vitro studies have shown that quercetin can reduce NF- κ B activation (blocking the nuclear translocation of p50 and p65 subunits) [82], the release of pro-inflammatory cytokines after LPS stimulation, and the production of ROS by directly inhibiting COX-2 and lipid peroxidation [96]. In addition, quercetin influences the expression of adhesion molecules (i.e., VCAM-1) and the release of metalloproteinases, thus contributing to the reduction of inflammatory tissue damage [96]. This anti-inflammatory effect has also been confirmed by experimental studies [97], while clinical data are still conflicting [96]. On the other hand, quercetin promotes Th1 response while reducing the secretion of Th2-produced cytokines [96][98], thus contributing to the host defense against viral infections. The actions of quercetin on lymphocyte function are complex, and the underlying molecular mechanisms are still undefined. However, the modulation of PI3K, protein kinase C (PKC), and JAK-STAT pathways plays a significant role [96][99][100]. Similar effects are evidenced in studies on the non-flavonoid curcumin. Indeed, this molecule can reduce the secretion of pro-inflammatory cytokines, the production of ROS and nitric oxide, and the expression of endothelial adhesion molecules and TLR-dependent signaling at different levels (downregulation of TLR expression, inhibition of TLR-activated kinases) [101][102]. Furthermore, in vitro studies show that curcumin impairs the antigen-presenting function of DCs [103], thus preventing the activation of adaptive immunity. Finally, curcumin modulates the activation of a wide number of transcription factors implicated in the immune response, including STAT3 and NF- κ B, by blocking their

translocation to the nucleus or the interaction with DNA [102], finally leading to complex, and not completely understood, effects on immunity [101][104].

References

1. Santini, A.; Cammarata, S.M.; Capone, G.; Ianaro, A.; Tenore, G.C.; Pani, L.; Novellino, E. Nutraceuticals: Opening the debate for a regulatory framework. *Br. J. Clin. Pharmacol.* 2018, **84**, 659–672.
2. Gombart, A.F.; Pierre, A.; Maggini, S. A Review of Micronutrients and the Immune System—Working in Harmony to Reduce the Risk of Infection. *Nutrients* 2020, **12**, 236.
3. Pecora, F.; Persico, F.; Argentiero, A.; Neglia, C.; Esposito, S. The Role of Micronutrients in Support of the Immune Response against Viral Infections. *Nutrients* 2020, **12**, 3198.
4. Peroni, D.G.; Trambusti, I.; Di Cicco, M.E.; Nuzzi, G. Vitamin D in pediatric health and disease. *Pediatric Allergy Immunol.* 2020, **31**, 54–57.
5. Camargo, C.A.; Ingham, T.; Wickens, K.; Thadhani, R.; Silvers, K.M.; Epton, M.J.; Town, G.I.; Pattemore, P.; Espinola, J.A.; Crane, J.; et al. Cord-blood 25-hydroxyvitamin D levels and risk of respiratory infection, wheezing, and asthma. *Pediatrics* 2011, **127**, e180–e187.
6. Martineau, A.R.; Jolliffe, D.A.; Hooper, R.L.; Greenberg, L.; Aloia, J.F.; Bergman, P.; Dubnov-Raz, G.; Esposito, S.; Ganmaa, D.; Ginde, A.A.; et al. Vitamin D supplementation to prevent acute respiratory tract infections: Systematic review and meta-analysis of individual participant data. *BMJ* 2017, **356**, i6583.
7. Lai, S.-H.; Liao, S.-L.; Tsai, M.-H.; Hua, M.-C.; Chiu, C.-Y.; Yeh, K.-W.; Yao, T.-C.; Huang, J.-L. Low cord-serum 25-hydroxyvitamin D levels are associated with poor lung function performance and increased respiratory infection in infancy. *PLoS ONE* 2017, **12**, e0173268.
8. Shiravi, A.-A.; Saadatkish, M.; Abdollahi, Z.; Miar, P.; Khanahmad, H.; Zeinalian, M. Vitamin D can be effective on the prevention of COVID-19 complications: A narrative review on molecular aspects. *Int. J. Vitam. Nutr. Res.* 2020.
9. Costagliola, G.; Spada, E.; Comberiati, P.; Peroni, D. Could nutritional supplements act as therapeutic adjuvants in COVID-19? *Ital. J. Pediatr.* 2021, in press.
10. Zelzer, S.; Prüller, F. Vitamin D Metabolites and Clinical Outcome in Hospitalized COVID-19. *Patients* 2021, **13**, 2129.
11. Carpagnano, G.E.; Di Lecce, V.; Quaranta, V.N.; Zito, A.; Buonamico, E.; Capozza, E.; Palumbo, A.; Di Gioia, G.; Valerio, V.N.; Resta, O. Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19. *J. Endocrinol. Investig.* 2021, **44**, 765–771.

12. Baktash, V.; Hosack, T.; Patel, N.; Shah, S.; Kandiah, P.; Van den Abbeele, K.; Mandal, A.K.J.; Missouris, C.G. Vitamin D status and outcomes for hospitalised older patients with COVID-19. *Postgrad. Med. J.* 2021, 97, 442–447.

13. Costagliola, G.; Spada, E.; Consolini, R. Age-related differences in the immune response could contribute to determine the spectrum of severity of COVID-19. *Immun. Inflamm. Dis.* 2021, in press.

14. Panfili, F.M.; Roversi, M.; D'Argenio, P.; Rossi, P.; Cappa, M.; Fintini, D. Possible role of vitamin D in Covid-19 infection in pediatric population. *J. Endocrinol. Investig.* 2021, 44, 27–35.

15. Zdrengea, M.T.; Makrinioti, H.; Bagacean, C.; Bush, A.; Johnston, S.L.; Stanciu, L.A. Vitamin D modulation of innate immune responses to respiratory viral infections. *Rev. Med Virol.* 2017, 27, e1909.

16. Hewison, M. Vitamin D and immune function: An overview. *Proc. Nutr. Soc.* 2012, 71, 50–61.

17. Sassi, F.; Tamone, C.; D'Amelio, P. Vitamin D: Nutrient, hormone, and immunomodulator. *Nutrients* 2018, 10, 1656.

18. Dankers, W.; Colin, E.M.; van Hamburg, J.P.; Lubberts, E. Vitamin D in autoimmunity: Molecular mechanisms and therapeutic potential. *Front. Immunol.* 2017, 7, 697.

19. Marino, R.; Misra, M. Extra-skeletal effects of vitamin D. *Nutrients* 2019, 11, 1460.

20. Medrano, M.; Carrillo-Cruz, E.; Montero, I.; Perez-Simon, J.A. Vitamin D: Effect on haematopoiesis and immune system and clinical applications. *Int. J. Mol. Sci.* 2018, 19, 2663.

21. Boonstra, A.; Barrat, F.J.; Crain, C.; Heath, V.L.; Savelkoul, H.F.; O'Garra, A. 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. *J. Immunol.* 2001, 167, 4974–4980.

22. Fisher, S.A.; Rahimzadeh, M.; Brierley, C.; Gration, B.; Doree, C.; Kimber, C.E.; Cajide, A.P.; Lamikanra, A.A.; Roberts, D.J. The role of vitamin D in increasing circulating T regulatory cell numbers and modulating T regulatory cell phenotypes in patients with inflammatory disease or in healthy volunteers: A systematic review. *PLoS ONE* 2019, 14, e0222313.

23. Chen, S.; Sims, G.P.; Chen, X.X.; Gu, Y.Y.; Chen, S.; Lipsky, P.E. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. *J. Immunol.* 2007, 179, 1634–1647.

24. Mora, J.R.; Iwata, M.; von Andrian, U.H. Vitamin effects on the immune system: Vitamins A and D take centre stage. *Nat. Rev. Immunol.* 2008, 8, 685–698.

25. Geldmeyer-Hilt, K.; Heine, G.; Hartmann, B.; Baumgrass, R.; Radbruch, A.; Worm, M. 1,25-dihydroxyvitamin D3 impairs NF-κB activation in human naïve B cells. *Biochem. Biophys. Res. Commun.* 2011, 407, 699–702.

26. Saggese, G.; Vierucci, F.; Prodam, F.; Cardinale, F.; Cetin, I.; Chiappini, E.; De' Angelis, G.L.; Massari, M.; Del Giudice, E.M.; Del Giudice, M.M.; et al. Vitamin D in pediatric age: Consensus of the Italian Pediatric Society and the Italian Society of Preventive and Social Pediatrics, jointly with the Italian Federation of Pediatricians. *Ital. J. Pediatrics* 2018, **44**, 1–40.

27. Holick, M.F.; Binkley, N.C.; Bischoff-Ferrari, H.A.; Gordon, C.M.; Hanley, D.A.; Heaney, R.P.; Murad, M.H.; Weaver, C.M. Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. *J. Clin. Endocrinol. Metab.* 2011, **96**, 1911–1930.

28. Legitimo, A.; Bertini, V.; Costagliola, G.; Baroncelli, G.I.; Morganti, R.; Valetto, A.; Consolini, R. Vitamin D status and the immune assessment in 22q11.2 deletion syndrome. *Clin. Exp. Immunol.* 2020, **200**, 272–286.

29. Brown, C.C.; Noelle, R.J. Seeing through the dark: New insights into the immune regulatory functions of vitamin A. *Eur. J. Immunol.* 2015, **45**, 1287–1295.

30. World Health Organization. Guideline: Vitamin A Supplementation in Infants and Children 6–59 Months of Age; World Health Organization: Geneva, Switzerland, 2011.

31. Mayo-Wilson, E.; Imdad, A.; Herzer, K.; Yakoob, M.Y.; Bhutta, Z.A. Vitamin A supplements for preventing mortality, illness, and blindness in children aged under 5: Systematic review and meta-analysis. *BMJ* 2011, **343**, d5094.

32. Chhagan, M.K.; Van den Broeck, J.; Luabeya, K.-K.; Mpontshane, N.; Tucker, K.L.; Bennish, M.L. Effect of micronutrient supplementation on diarrhoeal disease among stunted children in rural South Africa. *Eur. J. Clin. Nutr.* 2009, **63**, 850–857.

33. Hall, J.A.; Cannons, J.L.; Grainger, J.R.; Dos Santos, L.M.; Hand, T.W.; Naik, S.; Wohlfert, E.A.; Chou, D.; Oldenhove, G.; Robinson, M.; et al. Essential role for retinoic acid in the promotion of CD4(+) T cell effector responses via retinoic acid receptor alpha. *Immunity* 2011, **34**, 435–447.

34. Sirisinha, S. The pleiotropic role of vitamin A in regulating mucosal immunity. *Asian Pac. J. Allergy Immunol.* 2015, **33**, 71–89.

35. Sommer, A.; Djunaedi, E.; Loeden, A.; Tarwotjo, I.; West, J.R.K.; Tilden, R.; Mele, L. Impact of vitamin A supplementation on childhood mortality: A randomised controlled community trial. *Lancet* 1986, **327**, 1169–1173.

36. Cantorna, M.T.; Snyder, L.; Arora, J. Vitamin A and vitamin D regulate the microbial complexity, barrier function, and the mucosal immune responses to ensure intestinal homeostasis. *Crit. Rev. Biochem. Mol. Biol.* 2019, **54**, 184–192.

37. Rudraraju, R.; Jones, B.G.; Surman, S.L.; Sealy, R.E.; Thomas, P.G.; Hurwitz, J.L. Respiratory tract epithelial cells express retinaldehyde dehydrogenase ALDH1A and enhance IgA production by stimulated B cells in the presence of vitamin A. *PLoS ONE* 2014, **9**, e86554.

38. Seguin-Devaux, C.; Devaux, Y.; Latger-Cannard, V.; Grosjean, S.; Rochette-Egly, C.; Zannad, F.; Meistelman, C.; Mertes, P.M.; Longrois, D. Enhancement of the inducible NO synthase activation by retinoic acid is mimicked by RARalpha agonist in vivo. *Am. J. Physiol. Endocrinol. Metab.* 2002, 283, E525–E535.

39. Cassani, B.; Villablanca, E.J.; De Calisto, J.; Wang, S.; Mora, J.R. Vitamin A and immune regulation: Role of retinoic acid in gut-associated dendritic cell education, immune protection and tolerance. *Mol. Aspects Med.* 2012, 33, 63–76.

40. Iwata, M.; Eshima, Y.; Kagechika, H. Retinoic acids exert direct effects on T cells to suppress Th1 development and enhance Th2 development via retinoic acid receptors. *Int. Immunol.* 2003, 15, 1017–1025.

41. Dawson, H.D.; Collins, G.; Pyle, R.; Key, M.; Weeraratna, A.; Deep-Dixit, V.; Nadal, C.N.; Taub, D.D. Direct and indirect effects of retinoic acid on human Th2 cytokine and chemokine expression by human T lymphocytes. *BMC Immunol.* 2006, 7, 27.

42. Benson, M.J.; Pino-Lagos, K.; Rosemblatt, M.; Noelle, R.J. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. *J. Exp. Med.* 2007, 204, 1765–1774.

43. Lounder, D.T.; Khandelwal, P.; Dandoy, C.E.; Jodele, S.; Grimley, M.S.; Wallace, G.; Lane, A.; Taggart, C.; Teusink-Cross, A.C.; Lake, K.E.; et al. Lower levels of vitamin A are associated with increased gastrointestinal graft-versus-host disease in children. *Blood J. Am. Soc. Hematol.* 2017, 129, 2801–2807.

44. Hojyo, S.; Fukada, T. Roles of Zinc Signaling in the Immune System. *J. Immunol. Res.* 2016, 2016, 6762343.

45. Wessels, I.; Maywald, M.; Rink, L. Zinc as a Gatekeeper of Immune Function. *Nutrients* 2017, 9, 1286.

46. Maywald, M.; Wessels, I.; Rink, L. Zinc Signals and Immunity. *Int. J. Mol. Sci.* 2017, 18, 2222.

47. Read, S.A.; Obeid, S.; Ahlenstiel, C.; Ahlenstiel, G. The Role of Zinc in Antiviral Immunity. *Adv. Nutr.* 2019, 10, 696–710.

48. Haase, H.; Ober-Blöbaum, J.L.; Engelhardt, G.; Hebel, S.; Heit, A.; Heine, H.; Rink, L. Zinc signals are essential for lipopolysaccharide-induced signal transduction in monocytes. *J. Immunol.* 2008, 181, 6491–6502.

49. Gammoh, N.Z.; Rink, L. Zinc in Infection and Inflammation. *Nutrients* 2017, 9, 624.

50. Overbeck, S.; Rink, L.; Haase, H. Modulating the immune response by oral zinc supplementation: A single approach for multiple diseases. *Arch. Immunol. Ther. Exp.* 2008, 56, 15–30.

51. Bonaventura, P.; Benedetti, G.; Albarède, F.; Miossec, P. Zinc and its role in immunity and inflammation. *Autoimmun. Rev.* 2015, 14, 277–285.

52. Gruber, K.; Maywald, M.; Rosenkranz, E.; Haase, H.; Plumakers, B.; Rink, L. Zinc deficiency adversely influences interleukin-4 and interleukin-6 signaling. *J. Biol. Regul. Homeost. Agents* 2013, 27, 661–671.

53. Sanna, A.; Firinu, D.; Zavattari, P.; Valera, P. Zinc Status and Autoimmunity: A Systematic Review and Meta-Analysis. *Nutrients* 2018, 10, 68.

54. Prasad, A.S.; Bao, B.; Beck, F.W.; Sarkar, F.H. Zinc-suppressed inflammatory cytokines by induction of A20-mediated inhibition of nuclear factor- κ B. *Nutrition* 2011, 27, 816–823.

55. Tanaka, S.; Akaishi, E.; Hosaka, K.; Okamura, S.; Kubohara, Y. Zinc ions suppress mitogen-activated interleukin-2 production in Jurkat cells. *Biochem. Biophys. Res. Commun.* 2005, 335, 162–167.

56. Plum, L.M.; Brieger, A.; Engelhardt, G.; Hebel, S.; Nessel, A.; Arlt, M.; Kaltenberg, J.; Schwaneberg, U.; Huber, M.; Rink, L.; et al. PTEN-inhibition by zinc ions augments interleukin-2-mediated Akt phosphorylation. *Metalomics* 2014, 6, 1277–1287.

57. Wakabayashi, H.; Oda, H.; Yamauchi, K.; Abe, F. Lactoferrin for prevention of common viral infections. *J. Infect. Chemother.* 2014, 20, 666–671.

58. Peroni, D.G.; Fanos, V. Lactoferrin is an important factor when breastfeeding and COVID-19 are considered. *Acta Paediatr.* 2020, 109, 2139–2140.

59. Pammi, M.; Suresh, G. Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants. *Cochrane Database Syst. Rev.* 2020, 3, Cd007137.

60. Kell, D.B.; Heyden, E.L.; Pretorius, E. The Biology of Lactoferrin, an Iron-Binding Protein That Can Help Defend Against Viruses and Bacteria. *Front. Immunol.* 2020, 11, 1221.

61. Kruzel, M.L.; Zimecki, M.; Actor, J.K. Lactoferrin in a Context of Inflammation-Induced Pathology. *Front. Immunol.* 2017, 8, 1438.

62. Rosa, L.; Cutone, A.; Lepanto, M.S.; Paesano, R.; Valenti, P. Lactoferrin: A Natural Glycoprotein Involved in Iron and Inflammatory Homeostasis. *Int. J. Mol. Sci.* 2017, 18, 1985.

63. Egashira, M.; Takayanagi, T.; Moriuchi, M.; Moriuchi, H. Does daily intake of bovine lactoferrin-containing products ameliorate rotaviral gastroenteritis? *Acta Paediatr.* 2007, 96, 1242–1244.

64. Vitetta, L.; Coulson, S.; Beck, S.L.; Gramotnev, H.; Du, S.; Lewis, S. The clinical efficacy of a bovine lactoferrin/whey protein Ig-rich fraction (Lf/IgF) for the common cold: A double blind randomized study. *Complement. Ther. Med.* 2013, 21, 164–171.

65. Telang, S. Lactoferrin: A Critical Player in Neonatal Host Defense. *Nutrients* 2018, 10, 1228.

66. Manzoni, P. Clinical Benefits of Lactoferrin for Infants and Children. *J. Pediatr.* 2016, 173, S43–S52.

67. Vega-Bautista, A.; de la Garza, M.; Carrero, J.C. The Impact of Lactoferrin on the Growth of Intestinal Inhabitant Bacteria. *Int. J. Mol. Sci.* 2019, 20, 4707.

68. Levast, B.; Li, Z.; Madrenas, J. The role of IL-10 in microbiome-associated immune modulation and disease tolerance. *Cytokine* 2015, 75, 291–301.

69. Jang, Y.J.; Kim, W.K.; Han, D.H.; Lee, K.; Ko, G. *Lactobacillus fermentum* species ameliorate dextran sulfate sodium-induced colitis by regulating the immune response and altering gut microbiota. *Gut Microbes* 2019, 10, 696–711.

70. Siqueiros-Cendón, T.; Arévalo-Gallegos, S.; Iglesias-Figueroa, B.F.; García-Montoya, I.A.; Salazar-Martínez, J.; Rascón-Cruz, Q. Immunomodulatory effects of lactoferrin. *Acta Pharmacol. Sin.* 2014, 35, 557–566.

71. MacManus, C.F.; Collins, C.B.; Nguyen, T.T.; Alfano, R.W.; Jedlicka, P.; de Zoeten, E.F. VEN-120, a Recombinant Human Lactoferrin, Promotes a Regulatory T Cell [Treg] Phenotype and Drives Resolution of Inflammation in Distinct Murine Models of Inflammatory Bowel Disease. *J. Crohns Colitis* 2017, 11, 1101–1112.

72. Zimecki, M.; Mazurier, J.; Spik, G.; Kapp, J.A. Human lactoferrin induces phenotypic and functional changes in murine splenic B cells. *Immunology* 1995, 86, 122–127.

73. Actor, J.K.; Hwang, S.A.; Kruzel, M.L. Lactoferrin as a natural immune modulator. *Curr. Pharm. Des.* 2009, 15, 1956–1973.

74. Perdijk, O.; van Neerven, R.J.J. Bovine Lactoferrin Modulates Dendritic Cell Differentiation and Function. *Nutrients* 2018, 10, 848.

75. Zimecki, M.; Właszczyk, A.; Wojciechowski, R.; Dawiskiba, J.; Kruzel, M. Lactoferrin regulates the immune responses in post-surgical patients. *Arch. Immunol. Ther. Exp.* 2001, 49, 325–333.

76. Legrand, D.; Mazurier, J. A critical review of the roles of host lactoferrin in immunity. *Biometals* 2010, 23, 365–376.

77. He, Y.; Lawlor, N.T.; Newburg, D.S. Human Milk Components Modulate Toll-Like Receptor-Mediated Inflammation. *Adv. Nutr.* 2016, 7, 102–111.

78. Zheng, Y.; Qin, Z.; Ye, Q.; Chen, P.; Wang, Z.; Yan, Q.; Luo, Z.; Liu, X.; Zhou, Y.; Xiong, W.; et al. Lactoferrin suppresses the Epstein-Barr virus-induced inflammatory response by interfering with pattern recognition of TLR2 and TLR9. *Lab. Investig.* 2014, 94, 1188–1199.

79. Mohamed, W.A.; Schaalan, M.F. Antidiabetic efficacy of lactoferrin in type 2 diabetic pediatrics, controlling impact on PPAR- γ , SIRT-1, and TLR4 downstream signaling pathway. *Diabetol. Metab. Syndr.* 2018, 10, 89.

80. Kruzel, M.L.; Actor, J.K.; Zimecki, M.; Wise, J.; Płoszaj, P.; Mirza, S.; Kruzel, M.; Hwang, S.-A.; Ba, X.; Boldogh, I. Novel recombinant human lactoferrin: Differential activation of oxidative stress related gene expression. *J. Biotechnol.* 2013, 168, 666–675.

81. Ding, S.; Jiang, H.; Fang, J. Regulation of Immune Function by Polyphenols. *J. Immunol. Res.* 2018, 2018, 1264074.

82. Yahfoufi, N.; Alsadi, N.; Jambi, M.; Matar, C. The Immunomodulatory and Anti-Inflammatory Role of Polyphenols. *Nutrients* 2018, 10, 1618.

83. Filardo, S.; Di Pietro, M.; Mastromarino, P.; Sessa, R. Therapeutic potential of resveratrol against emerging respiratory viral infections. *Pharmacol. Ther.* 2020, 214, 107613.

84. Abba, Y.; Hassim, H.; Hamzah, H.; Noordin, M.M. Antiviral Activity of Resveratrol against Human and Animal Viruses. *Adv. Virol.* 2015, 2015, 184241.

85. Lin, S.C.; Ho, C.T.; Chuo, W.H.; Li, S.; Wang, T.T.; Lin, C.C. Effective inhibition of MERS-CoV infection by resveratrol. *BMC Infect. Dis.* 2017, 17, 144.

86. Malaguarnera, L. Influence of Resveratrol on the Immune Response. *Nutrients* 2019, 11, 946.

87. Jardim, F.R.; de Rossi, F.T.; Nascimento, M.X.; da Silva Barros, R.G.; Borges, P.A.; Prescilio, I.C.; De Oliveira, M.R. Resveratrol and Brain Mitochondria: A Review. *Mol. Neurobiol.* 2018, 55, 2085–2101.

88. Xia, N.; Daiber, A.; Förstermann, U.; Li, H. Antioxidant effects of resveratrol in the cardiovascular system. *Br. J. Pharmacol.* 2017, 174, 1633–1646.

89. Kavas, G.O.; Ayral, P.A.; Elhan, A.H. The effects of resveratrol on oxidant/antioxidant systems and their cofactors in rats. *Adv. Clin. Exp. Med.* 2013, 22, 151–155.

90. Yang, Y.; Li, S.; Yang, Q.; Shi, Y.; Zheng, M.; Liu, Y.; Chen, F.; Song, G.; Xu, H.; Wan, T.; et al. Resveratrol reduces the proinflammatory effects and lipopolysaccharide- induced expression of HMGB1 and TLR4 in RAW264.7 cells. *Cell. Physiol. Biochem.* 2014, 33, 1283–1292.

91. Chen, J.Q.; Szodoray, P.; Zeher, M. Toll-Like Receptor Pathways in Autoimmune Diseases. *Clin. Rev. Allergy Immunol.* 2016, 50, 1–17.

92. Schwager, J.; Richard, N.; Widmer, F.; Raederstorff, D. Resveratrol distinctively modulates the inflammatory profiles of immune and endothelial cells. *BMC Complement. Altern. Med.* 2017, 17, 309.

93. Diaz-Gerevini, G.T.; Repossi, G.; Dain, A.; Tarres, M.C.; Das, U.N.; Eynard, A.R. Beneficial action of resveratrol: How and why? *Nutrition* 2016, 32, 174–178.

94. Švajger, U.; Jeras, M. Anti-inflammatory effects of resveratrol and its potential use in therapy of immune-mediated diseases. *Int. Rev. Immunol.* 2012, 31, 202–222.

95. Zou, T.; Yang, Y.; Xia, F.; Huang, A.; Gao, X.; Fang, D.; Xiong, S.; Zhang, J. Resveratrol Inhibits CD4+ T cell activation by enhancing the expression and activity of Sirt1. *PLoS ONE* 2013, 8, e75139.

96. Li, Y.; Yao, J.; Han, C.; Yang, J.; Chaudhry, M.T.; Wang, S.; Liu, H.; Yin, Y. Quercetin, Inflammation and Immunity. *Nutrients* 2016, 8, 167.

97. Rivera, L.; Morón, R.; Sánchez, M.; Zarzuelo, A.; Galisteo, M. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. *Obesity* 2008, 16, 2081–2087.

98. Nair, M.P.; Kandaswami, C.; Mahajan, S.; Chadha, K.C.; Chawda, R.; Nair, H.; Kumar, N.; Nair, R.E.; Schwartz, S.A. The flavonoid, quercetin, differentially regulates Th-1 (IFNgamma) and Th-2 (IL4) cytokine gene expression by normal peripheral blood mononuclear cells. *Biochim. Biophys. Acta* 2002, 1593, 29–36.

99. Endale, M.; Park, S.C.; Kim, S.; Kim, S.H.; Yang, Y.; Cho, J.Y.; Rhee, M.H. Quercetin disrupts tyrosine-phosphorylated phosphatidylinositol 3-kinase and myeloid differentiation factor-88 association, and inhibits MAPK/AP-1 and IKK/NF-κB-induced inflammatory mediators production in RAW 264.7 cells. *Immunobiology* 2013, 218, 1452–1467.

100. Kempuraj, D.; Madhappan, B.; Christodoulou, S.; Boucher, W.; Cao, J.; Papadopoulou, N.; Cetrulo, C.L.; Theoharides, T.C. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. *Br. J. Pharmacol.* 2005, 145, 934–944.

101. Catanzaro, M.; Corsini, E. Immunomodulators Inspired by Nature: A Review on Curcumin and Echinacea. *Molecules* 2018, 23, 2778.

102. Burge, K.; Gunasekaran, A.; Eckert, J.; Chaaban, H. Curcumin and Intestinal Inflammatory Diseases: Molecular Mechanisms of Protection. *Int. J. Mol. Sci.* 2019, 20, 1912.

103. Kim, G.Y.; Kim, K.H.; Lee, S.H.; Yoon, M.S.; Lee, H.J.; Moon, D.O.; Lee, C.-M.; Ahn, S.-C.; Park, Y.C.; Park, Y.-M. Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-kappa B as potential targets. *J. Immunol.* 2005, 174, 8116–8124.

104. Cianciulli, A.; Calvello, R.; Porro, C.; Trotta, T.; Salvatore, R.; Panaro, M.A. PI3k/Akt signalling pathway plays a crucial role in the anti-inflammatory effects of curcumin in LPS-activated microglia. *Int. Immunopharmacol.* 2016, 36, 282–290.

Retrieved from <https://encyclopedia.pub/entry/history/show/30564>